US clears first new sunscreen filter in over two decades

Overview

Updated Aug 9

For more than 25 years, US sunscreen makers worked from the same short list of ultraviolet filters. On August 9, 2026, an FDA order let them start using a new one.

The filter, bemotrizinol, blocks both UVA and UVB rays and stays stable in sunlight. It has protected skin in Europe and Asia since 1999. Now it can go into Neutrogena, Aveeno, and other US brands.

Why it matters

Americans gain access to a stronger, more stable broad-spectrum filter that has guarded European and Asian skin for 25 years.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

25+ years

Since the last new filter

No new active UV filter had joined the US over-the-counter sunscreen monograph since the late 1990s.

Maximum concentration allowed

The FDA permits bemotrizinol in US sunscreen formulas at up to 6%.

18 months

Exclusive rights for DSM-Firmenich

The chemicals maker holds sole supply rights before rivals can sell the filter.

8,510

Projected US melanoma deaths, 2026

The American Cancer Society estimates 8,510 melanoma deaths and 112,000 invasive cases this year.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Organizations Involved

U.S. Food and Drug Administration

Federal regulatory agency

Issued the order clearing bemotrizinol

The agency regulates US sunscreens as over-the-counter drugs, a stricter path than the cosmetic rules used in Europe.

DSM-Firmenich

Chemicals and Ingredients Maker

Holds 18-month exclusive supply rights

The company sells bemotrizinol to sunscreen makers under the brand name Parsol Shield.

Kenvue Inc.

Consumer Health Company

Plans to use bemotrizinol in its brands

Kenvue owns Neutrogena and Aveeno, two of the largest US sunscreen brands.

Timeline

January 2005 August 2026

4 events Latest: August 9th, 2026 · 1 month ago

Tap a bar to jump to that date

August 2026
Filter becomes usable in US products
Latest Milestone

The FDA order takes effect. Manufacturers may now legally add bemotrizinol, though finished products will reach shelves later.
August 9th, 2026
June 2026
FDA declares bemotrizinol safe and effective
Regulatory

The agency issues its final order classifying the filter as safe and effective for adults and children six months and older.
June 9th, 2026
November 2014
Sunscreen Innovation Act becomes law
Legislation

Congress passes a law to speed FDA review of new sunscreen filters, targeting a backlog of eight pending applications.
November 26th, 2014
January 2005
First US application filed
Regulatory

Ciba Specialty Chemicals asks the FDA to allow bemotrizinol in US sunscreens. The request then stalls for years.
January 1st, 2005

Scenarios

Bemotrizinol sunscreens reach US shelves within a year

Likely Resolves by Aug 9, 2027

Discussed by: Kenvue, Consumer Reports, and dermatology outlets covering the approval

DSM-Firmenich supplies Parsol Shield, and Kenvue reformulates Neutrogena or Aveeno products around it. After stability and SPF testing, the first US bottles containing bemotrizinol go on sale at national retailers within the first year of the order.

FDA clears a second new UV filter

Possible Resolves by End of 2028

Discussed by: Environmental Working Group and sunscreen-industry trade press

Bemotrizinol's approval breaks a long logjam of pending filter applications. Encouraged suppliers submit fresh safety data, and the FDA determines another new ultraviolet filter safe and effective for over-the-counter use, widening the US filter list further.

No finished product on shelves in 2026

Likely Resolves by End of 2026

Discussed by: Medical Daily and other outlets noting the gap between legal use and retail availability

August 9 is only the date the filter becomes legal to use. Reformulation, stability testing, and new labeling take months. Under this scenario, no bemotrizinol sunscreen actually reaches US store shelves before the end of 2026.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1999

Europe clears bemotrizinol (1999)

European regulators approved bemotrizinol for sunscreens, treating it as a cosmetic ingredient. Brands sold it under names including Tinosorb S and Parsol Shield. It became a common broad-spectrum filter across Europe and Asia.

Then

European sunscreens gained a stable filter with strong UVA coverage well before US shoppers could buy it.

Now

A widening gap opened between US and international sunscreen formulas that lasted more than 25 years.

Why this matters now

The 27-year lag shows how differently the US and Europe regulate the same ingredient. Bemotrizinol was routine abroad long before the FDA cleared it.

November 2014

Sunscreen Innovation Act (2014)

Congress passed a law to force faster FDA review of new sunscreen filters. Eight applications were stuck, some pending for over a decade. Lawmakers set deadlines for the agency to act.

Then

The FDA issued proposed orders but found the safety data insufficient to clear the pending filters.

Now

No new filter reached the market for another decade, showing that a deadline alone could not resolve the FDA's data demands.

Why this matters now

Bemotrizinol is the first filter to clear the process the 2014 law tried to speed up. It shows what it finally took to get one through.

February 2019

FDA proposed sunscreen rule (2019)

The FDA proposed rules asking for more safety data on common chemical filters after studies showed some, like oxybenzone, were absorbed into the bloodstream. The agency wanted to know what that absorption meant.

Then

The proposal left the safety status of several older filters unsettled and raised the bar for new ones.

Now

Blood absorption became a central test for any filter seeking US approval.

Why this matters now

Bemotrizinol cleared that bar. Its very low absorption into the bloodstream was central to the FDA's safe-and-effective ruling.